PF-AtlasКлинические испытания › NCT02333058

Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies

Treosulfan · Фаза 2

ID реестра
NCT02333058
Фаза
Фаза 2
Статус
Завершено
Препарат / вмешательство
Treosulfan
Спонсор
medac GmbH
Начало
2014-11-21
Набор участников
70
Центры
24

Об исследовании

The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a standardised Fludarabine-containing conditioning and to contribute to the current pharmacokinetic model to be able to finally give age (or body surface area) dependent dose recommendations. The treatment regimens given in the protocol MC-FludT.17/M are based on sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic haematopoietic stem cell transplantation of the selected patient population, the risk-benefit assessment is therefore reasonably in favour of the study conduct.

Открыть NCT02333058 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT02333058 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.